TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04974125

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drain
Description: A 10 mm suction drain is placed through a trocar in the right hypochondrium (liver).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual exsufflation
Description: Exsufflation through the trocar opening.
Study: NCT05704049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Background Treatment/Rescue medication; ATC code: H02AB04; Pharmaceutical form: As per local commercial product; Route of administration: IV
Study: NCT06346535

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Digital Cognitive Testing performed at home.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cognitive Testing
Description: Digital Cognitive Testing performed at home.
Study: NCT06448390

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical training
Description: The patients are randomized to either walking 30 minutes 3 times a week or lifting the body to a tip toe position three times a day until pain in the claves and then add another five liftings before ending the session
Study: NCT05958433

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation with stoma appliance
Description: The rehabilitation group will receive preoperative stoma education in addition, a water-filled ostomy appliance (50-100 ml) will be attached 48 hours before surgery. These pouches will not be removed until surgery, and the EST nurse will teach the patients preoperatively how to manage the ostomy appliance with similar standards as described in the usual postoperative stoma care.
Study: NCT06554496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP Treatment
Description: Continuous Positive Airway Pressure (CPAP) therapy will be administered to patients for 3 months. The CPAP device will be set to deliver a continuous flow of air at a prescribed pressure to keep the patient's airway open during sleep.
Study: NCT06508450

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Component C
Description: Content addresses community and environmental barriers and facilitators to on-going engagement with services and self-efficacy.
Study: NCT06434805

Intervention type: OTHER
Group type: OTHER
Intervention: sex workers and sexual minorities education workshop
Description: The participants will receive a one-day workshop (four sessions). The generic content aims at enhancing the understanding of sexual orientation, gender identities, social stigma, sex work and sexual orientation and human rights (session 1), the lived experience of SWSM (session 2), the content specifically related to the medical and healthcare field, including be familiar with the professional and ethical obligations (session 3), the skills that can be adopted when providing services to SWSM (session 4).
Study: NCT04790968

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET
Description: Prostate specific membrane antigen positron emission tomography

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET/MRI
Description: Prostate specific membrane antigen positron emission tomography combined with magnetic resonance imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA-PET/CT
Description: Prostate specific membrane antigen positron emission tomography combined with computed tomography imaging
Study: NCT05405166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isatuximab IV
Description: Pharmaceutical form: Concentrate solution for IV infusion; Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab SC
Description: Pharmaceutical form: Solution for subcutaneous administration; Route of administration: Subcutaneous (SC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: Tablet; Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pharmaceutical form: hard capsules; Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pharmaceutical form: hard capsules; Route of administration: Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; Auxiliary Medicinal Product (AxMP) i.e., background treatment; ATC code: H02AB02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: R03DC03

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol / Acetaminophen
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol / Acetaminophen
Description: Pharmaceutical form: As per local commercial product; Route of administration: Oral; AxMP i.e., background treatment; ATC code: N02BE01
Study: NCT06005714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mindeudesivir hydrobromide tablets and Clarithromycin tablets
Description: Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.
Study: NCT05405166

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication- oral; for management of infusion reactions-IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: R06AA02

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Pharmaceutical form: As per local commercial product; Route of administration: As premedication-IV; for management of infusion reactions- IV (or oral equivalent); AxMP i.e., background treatment and rescue medication (in case of infusion reactions); ATC code: H02AB04
Study: NCT05379985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RMC-6236
Description: Oral Tablets
Study: NCT04941898

Intervention type: BIOLOGICAL
Intervention: PEGylated Recombinant Factor VIII
Description: Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
Study: NCT06005714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mindeudesivir hydrobromide tablets and Clarithromycin tablets
Description: Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and clarithromycin tablets are administered twice from D1 to D10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mindeudesivir hydrobromide tablets and Cyclosporine softgels
Description: Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mindeudesivir hydrobromide tablets and Cyclosporine softgels
Description: Mindeudesivir hydrobromide tablets are administered once at D1 and D4, and cyclosporine sofgels are administered once at D4.
Study: NCT05870007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20 Mg Oral Tablet
Description: Atorvastatin 20mg
Study: NCT06274047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given by PO
Study: NCT06274047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Given by PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen Deprivation Therapy
Description: Given by PO
Study: NCT06582641

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Group Connection - Middle School (PGC-MS)
Description: Peer Group Connection - Middle School (PGC-MS) is the treatment condition. PGC-MS is a school-based positive youth development program for students entering the transition year into middle school (6th or 7th grade). PGC-MS aims to improve school engagement and social-emotional learning skills that support adolescent health and educational outcomes for program participants. Participants receive 45-minute outreach sessions held 3 to 4 times per month for the full school year. Schools are expected to implement a minimum of 18 outreach sessions over the school year. PGC-MS outreach sessions are delivered by older peer leaders (8th, 9th, or 10th graders) who are carefully selected by faculty advisors and trained on how to deliver program content.
Study: NCT06160440

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SC1011
Description: Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: Each subject in the SAD groups participated in 1 treatment period only and reside at the clinical research unit (CRU) from Day -1 (the day before dosing) to Day 7 (144 hours post dose).
Study: NCT05816187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program on healthy habits
Description: 6-week supervised educational program.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education program on healthy habits
Description: 6-week supervised educational program.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual
Description: The same therapeutic exercise protocol will be scheduled which will be carried out autonomously without supervision with telephone tracking
Study: NCT05165966

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dosage of COVID-19 vaccine (Vero cell), Inactivated
Description: High-dose COVID-19 Vaccine(Vero Cell),Inactivated:1200SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated
Description: Medium-dose COVID-19 Vaccine(Vero Cell),Inactivated: 600SU inactivated SARS-CoV-2 virus in 0.5 mL of aluminium hydroxide solution per injection
Study: NCT05870007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Bicarbonate 600 Mg Oral Tablet
Description: Sodium bicarbonate would be titrated up to 1800mg per day according to metabolic acidosis severity during clinical follow-up
Study: NCT06408831

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Classroom Teaching University Students Intervention Group
Description: Web-based cyber sexual violence training and counseling will be provided to female classroom teaching students, who are the intervention group, and the effect of the intervention on cyber sexual violence experience, sensitivity and cyber security will be examined.
Study: NCT04988126

Intervention type: OTHER
Intervention: Interventions
Description: Observational study, not applicable
Study: NCT04707183

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine IV Infusion
Description: Lidocaine will infused through erector spinae plane block catheter in patients with traumatic rib fracture.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% Lidocaine via ESPB
Description: 10 ml of 2% lidocaine will be infused through ESPB in treatment group
Study: NCT01179997

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocardiographic optimization of the interventricular pacing delay according to QRS width
Study: NCT06425978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cellular Matrix / A-CP-HA Kit
Description: For infiltration, a prior preparation of the region with anesthetic cream is performed, procaine 25 mg/g + lidocaine 25 mg/g (Emla 5% cream) in the vulvar area and vaginal introitus. Occlusion of the area with plastic film is performed for 20 minutes. After asepsis and antisepsis, infiltration is performed with mesotherapy needles 31G 4mm, using the technique of superficial point-to-point mesotherapy microinjections, in the vestibule and the first 3 cm of the posterior wall of the vagina.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local estrogen therapy (Blissel, estriol 50 micrograms/g vaginal gel)
Description: Blissel®, Estriol vaginal gel 50 micrograms/g, daily application for 15-21 days in a row, then two times a week for 24 weeks (6 months). Application instructions will be explained to the patients. The gel should be applied in the vagina using an applicator with the marked dose, the full applicator should be inserted into the vagina and emptied, preferably at night.
Study: NCT06068725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training videos
Description: After determining the application and control groups in the research, the purpose of the research was explained to both groups. The mobile phone usage skills of the individuals who will be included in the application group were evaluated with the Digital Literacy Scale. Training videos for 15 people each (30 minutes in total) regarding symptom management were shared on the phones of the patients/relatives in the application groups, and the patients and their relatives were informed and watched the training video. Data collection forms would be filled out before the application (Z0), on the 30th day of the application (Z1), and on the 90th day of the application (Z2).
Study: NCT05440955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: left fronto-temporal transcranial Direct Current Stimulation (tDCS)
Description: The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: left fronto-temporal transcranial Direct Current Stimulation (tDCS)
Description: The study intervention consists of ten 20-minutes sessions of active or sham tDCS. Sessions will be delivered twice daily and separated by at least 2 hours for 5 consecutive weekdays. The electric current will be generated by an electric stimulator (class IIa medical device). During the entire tDCS session, the subject is at rest, comfortably seated in a chair in a quiet room. A clinician will be present for the entire session duration. The current will be applied via a pair of rubber electrodes (35 cm²) placed on the surface of the scalp. The anode will be placed over the left dorsolateral prefrontal cortex. The cathode will be placed over the left auditory cortex. The stimulation parameters will be set at 2-mA for 20 minutes, with a progressive increase during the first 30-sec and a progressive decrease during the last 30-sec of each session. The impedance of the applied current is monitored by the stimulator during each session.
Study: NCT05582577

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab injection with subthreshold micropulse laser
Description: Group A: intravitreal interjection of Bevacizumab and subthreshold micropulse laser

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravitreal bevacizumab injection alone
Description: Group B: Intravitreal injection of Bevacizumab alone
Study: NCT05799144

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DNA Vaccine
Description: Given pBI-11 IM

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Papillomavirus Tumor Antigen Vaccine
Description: Given into a muscle

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given into vein

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Description: Undergo a CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Undergo an MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study: NCT05275218

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implementation of the KDIGO bundle)
Description: Comprehensive Implementation of the Bundle recommended by the Kidney Disease: Improving Global Outcomes Group (KDIGO bundle)
Study: NCT05335083

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: A positive CPAP intervention
Study: NCT05208983

Intervention type: BIOLOGICAL
Intervention: mRNA Vaccines or Viral vector-based vaccines for COVID
Description: Participants receiving an approved COVID vaccine

Intervention type: BIOLOGICAL
Intervention: mRNA Vaccines or Viral vector-based vaccines for COVID
Description: Participants receiving an approved COVID vaccine
Study: NCT05242588

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005
Description: 30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005
Description: 30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS005
Description: 30 subjectes in JS005 150mg chort, JS005 300mg chort, and JS005 450mg chort receive JS005 150mg, JS005 300mg and JS005 450mg subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 subjects in JS005 150mg chort, JS005 300mg chort, and JS005 450mgchort receive the placebo subcutaneous injection seperately at Week 0, 1, 2, and 3, and monthly dose starting at Week 4 (dosing in Week 4, 8, and 12).